ZAI LAB LTD0000006 (1ZLB) - Total Liabilities
Based on the latest financial reports, ZAI LAB LTD0000006 (1ZLB) has total liabilities worth €456.88 Million EUR (≈ $534.15 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ZAI LAB LTD0000006 (1ZLB) cash conversion ratio to assess how effectively this company generates cash.
ZAI LAB LTD0000006 - Total Liabilities Trend (2021–2025)
This chart illustrates how ZAI LAB LTD0000006's total liabilities have evolved over time, based on quarterly financial data. Check ZAI LAB LTD0000006 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
ZAI LAB LTD0000006 Competitors by Total Liabilities
The table below lists competitors of ZAI LAB LTD0000006 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rendong Holdings Co Ltd
SHE:002647
|
China | CN¥4.46 Billion |
|
Electra Ltd
TA:ELTR
|
Israel | ILA10.12 Billion |
|
Suzhou TZTEK Technology Co Ltd
SHG:688003
|
China | CN¥1.98 Billion |
|
Central China Securities Co Ltd
SHG:601375
|
China | CN¥42.83 Billion |
|
Perdoceo Education Corp
NASDAQ:PRDO
|
USA | $301.53 Million |
|
Penn National Gaming Inc
NASDAQ:PENN
|
USA | $12.44 Billion |
|
Oesterr. Post AG
VI:POST
|
Austria | €5.57 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down ZAI LAB LTD0000006's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of ZAI LAB LTD0000006.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ZAI LAB LTD0000006's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ZAI LAB LTD0000006 (2021–2025)
The table below shows the annual total liabilities of ZAI LAB LTD0000006 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €456.88 Million ≈ $534.15 Million |
+32.49% |
| 2024-12-31 | €344.86 Million ≈ $403.17 Million |
+43.58% |
| 2023-12-31 | €240.18 Million ≈ $280.79 Million |
+37.60% |
| 2022-12-31 | €174.54 Million ≈ $204.06 Million |
-24.11% |
| 2021-12-31 | €230.00 Million ≈ $268.89 Million |
-- |
About ZAI LAB LTD0000006
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more